Prescription Drugs Market Research Reports & Industry Analysis
The prescription drugs industry is a key cornerstone of healthcare, delivering vital medications that improve and save lives. As this industry continues to evolve, understanding its nuances can be an ongoing challenge. MarketResearch.com provides hundreds of authoritative prescription drugs market research reports to help stakeholders understand the shifting market landscape and devise effective business strategies.
The Latest Prescription Drugs Market Analysis
- We provide data-packed reports on a wide range of product types, therapeutic areas, regions, and companies.
- Our research includes in-depth analyses of prescription drug market size, growth forecasts, and drivers and challenges.
- In addition, we cover the rise of personalized medicine and gene therapies, as well as regulatory issues and pricing models.
Your Dedicated Research Partner
As the prescription drugs industry shifts and changes, MarketResearch.com equips you with the tools to thrive. Trusted for decades as a reliable research partner, our clients include top pharmaceutical companies, investment banks, and universities. Whether you are exploring new markets or seeking to futureproof your business, our prescription drugs industry research reports offer a wealth of knowledge to inform your strategy. Get started by exploring our vast selection of reports on the prescription drugs industry today.
Prescription Drugs Industry Research & Market Reports
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. Growth ... Read More
-
Anxiolytics
... 4.6% over the analysis period 2024-2030. The U.S. Market is Estimated at US$259.8 Million While China is Forecast to Grow at 7.1% CAGR The Anxiolytics market in the U.S. is estimated at US$259.8 Million in ... Read More
-
Pediatric Epilepsy Therapeutics
... at a CAGR of 3.3% over the analysis period 2024-2030. Third Generation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$7.0 Billion by the end of ... Read More
-
Animal Medication
... CAGR of 4.5% over the analysis period 2024-2030. Companion Animals, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$20.7 Billion by the end of the analysis ... Read More
-
India Pharmaceuticals and Medicine - Industry Report
... Seek out the most attractive acquisition opportunities • Analyse industry trends • Benchmark their own financial performance Using an exclusive methodology, a quick glance of this Pharmaceuticals and Medicine (India) report will tell you the ... Read More
-
Belgium Pharmaceuticals - Industry Report
... attractive acquisition opportunities • Analyse industry trends • Benchmark their own financial performance Using an exclusive methodology, a quick glance of this Pharmaceuticals (Belgium) report will tell you the companies that have a declining financial ... Read More
-
Oral Solid Dosage Contract Manufacturing Global Market Report 2025
... solid dosage contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025
... solid dosage pharmaceutical formulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Cannabis Production in Canada - Industry Market Research Report
... in 2013, producers have grown continuously as they invest in production capabilities to produce quality products. As consumers shifted from illegal cannabis purchases to the licensed recreational market, cannabis growers have grown significantly, but revenue ... Read More
-
Cardiovascular Drugs
... CAGR of 3.4% over the analysis period 2024-2030. Anticoagulants, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$57.7 Billion by the end of the analysis period. ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Antidepressants
... 2.5% over the analysis period 2024-2030. Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end of the analysis period. ... Read More
-
Iron Deficiency Anemia Therapy
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Oral Iron Therapy, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$11.1 Billion by ... Read More
-
Spinal Cord Trauma Treatment
... 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$1.7 Billion by the end ... Read More
-
Substance Abuse Treatment
... at a CAGR of 7.2% over the analysis period 2024-2030. Nicotine Addiction Treatment, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$9.4 Billion by the end ... Read More
-
Glioblastoma Multiforme Treatment (GBM)
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the ... Read More
-
Genitourinary Drugs
... CAGR of 2.3% over the analysis period 2024-2030. Urologicals, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Cryptococcosis Treatment
... CAGR of 4.5% over the analysis period 2024-2030. Amphotericin B, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$5.5 Billion by the end of the analysis ... Read More
-
Eye Allergy Therapeutics
... at a CAGR of 5.5% over the analysis period 2024-2030. Antihistamines, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$2.2 Billion by the end of the ... Read More
-
Anti-Obesity Drugs
... CAGR of 8.7% over the analysis period 2024-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis ... Read More
-
Endometriosis Drugs
... CAGR of 3.0% over the analysis period 2024-2030. Hormone therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end of the analysis ... Read More
-
Scoliosis Management
... CAGR of 4.1% over the analysis period 2024-2030. Thoracolumbosacral Orthosis (TLSO), one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$3.2 Billion by the end of the ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Proton Pump Inhibitors (PPIs)
... 2030, growing at a CAGR of 3.1% over the analysis period 2024-2030. Over the Counter PPIs, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$2.2 Billion ... Read More
-
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs
... Billion by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Lipopeptide, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$1.7 Billion by ... Read More
Research Assistance
